Deciphera Pharmaceuticals, Inc. (DCPH)
Fuera de horario:
Deciphera Pharmaceuticals, Inc.
200 Smith Street
Waltham, MA 02451
United States
781 209 6400
https://www.deciphera.com
Sector(es): Healthcare
Industria: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 355
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Steven L. Hoerter | President, CEO & Director | 1.24M | N/D | 1971 |
| Mr. Thomas Patrick Kelly J.D. | Executive VP, CFO & Treasurer | 772.47k | N/D | 1971 |
| Dr. Dashyant Dhanak Ph.D. | Executive VP & Chief Scientific Officer | 498.45k | N/D | 1963 |
| Mr. Daniel C. Martin | Senior VP & Chief Commercial Officer | 727.53k | N/D | 1975 |
| Dr. Matthew L. Sherman M.D. | Executive VP & Chief Medical Officer | 870.58k | N/D | 1956 |
| Dr. Kevin Brodbeck Ph.D. | Senior VP & Chief Technical Officer | N/D | N/D | N/D |
| Jennifer Larson | Senior Vice President of Finance & Investor Relations | N/D | N/D | N/D |
| Mr. Jeffrey M. Held J.D. | Senior VP & General Counsel | N/D | N/D | N/D |
| Ms. Lisa Amaya Price | Senior VP & Chief Human Resources Officer | N/D | N/D | N/D |
| Ms. Jama Pitman | Senior VP & Chief Development Officer | N/D | N/D | 1979 |
Descripción
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
Gestión corporativa
La calificación ISS Governance QuickScore de Deciphera Pharmaceuticals, Inc. a partir del 1 de mayo de 2024 es 8. Las puntuaciones principales son Auditoría: 7; Junta: 6; Derechos del accionista: 8; Compensación: 9.
